Dosie™ for I-PDT
Malignant Pleural Mesothelioma
Key Facts
About Simphotek
Simphotek, founded in 2006, is a private biotechnology company pioneering computational medical devices for Photodynamic Therapy (PDT). Its platform, centered on the Dosie™ treatment planning system and the underlying SimphoSOFT® simulation software, is designed to make PDT more precise, effective, and accessible for treating advanced cancers. With strong academic partnerships, government grant funding, and a focus on cancers with high unmet need, Simphotek is advancing a first-in-class platform to establish PDT as a standard-of-care alternative to conventional therapies.
View full company profileAbout Simphotek
Simphotek, founded in 2006, is a private biotechnology company pioneering computational medical devices for Photodynamic Therapy (PDT). Its platform, centered on the Dosie™ treatment planning system and the underlying SimphoSOFT® simulation software, is designed to make PDT more precise, effective, and accessible for treating advanced cancers. With strong academic partnerships, government grant funding, and a focus on cancers with high unmet need, Simphotek is advancing a first-in-class platform to establish PDT as a standard-of-care alternative to conventional therapies.
View full company profileTherapeutic Areas
Other Malignant Pleural Mesothelioma Drugs
| Drug | Company | Phase |
|---|---|---|
| Galinpepimut-S (GPS) | SELLAS Life Sciences | Phase 2 |
| Radspherin | Oncoinvent | Preclinical |